US health regulators have approved a blood clot preventer developed by [b]Merck & Co[/b] for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.
The drug, vorapaxar, was approved to reduce the risk of heart attacks, stroke, cardiovascular death and the need for procedures to improve blood flow to the heart, the [b]US Food and Drug Administration[/b] said. Merck will sell the new medicine under the brand name Zontivity.
[link url=http://www.reuters.com/article/2014/05/08/us-merck-fda-idUSKBN0DO1OF20140508]Full Reuters Health report[/link]